Eversept Partners, LP Immunovant, Inc. Transaction History
Eversept Partners, LP
- $1.33 Billion
- Q1 2024
A detailed history of Eversept Partners, LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Eversept Partners, LP holds 255,526 shares of IMVT stock, worth $7.03 Million. This represents 0.62% of its overall portfolio holdings.
Number of Shares
255,526
Previous 113,793
124.55%
Holding current value
$7.03 Million
Previous $4.79 Million
72.22%
% of portfolio
0.62%
Previous 0.47%
Shares
11 transactions
Others Institutions Holding IMVT
# of Institutions
238Shares Held
62.9MCall Options Held
1.46MPut Options Held
546K-
Vanguard Group Inc Valley Forge, PA6.48MShares$178 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.48MShares$123 Million0.0% of portfolio
-
State Street Corp Boston, MA3.64MShares$100 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.96MShares$81.5 Million2.01% of portfolio
-
Armistice Capital, LLC New York, NY2.16MShares$59.5 Million0.95% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...